The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.